Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.49 |
| ▸ | CTSL | P07711 | 4/20 | 0.40 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.38 |
| ▸ | CNR2 | P34972 | 4/20 | 0.38 |
| ▸ | NTSR1 | P30989 | 4/20 | 0.38 |
| ▸ | CTSS | P25774 | 3/20 | 0.37 |
| ▸ | CTSK | P43235 | 3/20 | 0.37 |
| ▸ | CCR1 | P32246 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4127971 | 0.88 | TRPV4 (0.49) | TRPV4CTSLCAPN1MAPT | |
| SCHEMBL13872514 | 0.88 | TRPV4 (0.49) | TRPV4CTSLCAPN1MAPT | |
| SCHEMBL14605683 | 0.82 | TRPV4 (0.47) | TRPV4CTSLCAPN1CNR2NTSR1 | |
| SCHEMBL13872524 | 0.82 | TRPV4 (0.47) | TRPV4CTSLCAPN1CNR2NTSR1 | |
| SCHEMBL4132372 | 0.82 | TRPV4 (0.47) | TRPV4CTSLCAPN1CNR2NTSR1 | |
| SCHEMBL4127488 | 0.78 | TRPV4 (0.76) | TRPV4CTSLCTSSCTSK | |
| SCHEMBL4127926 | 0.78 | TRPV4 (0.76) | TRPV4CTSLCTSSCTSK | |
| SCHEMBL4136044 | 0.78 | TRPV4 (0.52) | TRPV4CTSLCTSSCTSKCCR1 | |
| SCHEMBL4129714 | 0.77 | TRPV4 (0.60) | TRPV4CTSLCAPN1CNR2CTSS | |
| SCHEMBL4139857 | 0.77 | TRPV4 (0.55) | TRPV4CTSLCTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105259-A1 | Acyclic 1,4-Diamines and Uses Thereof | SMITHKLINE BEECHAM CORPORATION | 2009-04-23 | — | — | US | claimed |
| US-20090105259-A1 | Acyclic 1,4-Diamines and Uses Thereof | SMITHKLINE BEECHAM CORPORATION | 2009-04-23 | — | — | US | disclosed |
| WO-2007030761-A2 | ACYCLIC 1,4-DIAMINES AND USES THEREOF | SMITHKLINE BEECHAM CORPORATION (US) | 2007-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105259-A1 | Acyclic 1,4-Diamines and Uses Thereof | TRPV4, TRPC4, TRPV1 | TRPV4 1/4885CTSL 3815/4885CAPN1 2031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.